- Home
- IMCR vs OMCL Comparison
IMCR vs OMCL Comparison
Compare IMCR & OMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- OMCL
- Stock Information
- Founded
- IMCR 2008
- OMCL 1992
- Country
- IMCR United Kingdom
- OMCL United States
- Employees
- IMCR N/A
- OMCL N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- OMCL Computer Manufacturing
- Sector
- IMCR Health Care
- OMCL Technology
- Exchange
- IMCR Nasdaq
- OMCL Nasdaq
- Market Cap
- IMCR 1.5B
- OMCL 1.5B
- IPO Year
- IMCR 2021
- OMCL 2001
- Fundamental
- Price
- IMCR $28.40
- OMCL $25.78
- Analyst Decision
- IMCR Buy
- OMCL Buy
- Analyst Count
- IMCR 11
- OMCL 6
- Target Price
- IMCR $59.11
- OMCL $45.83
- AVG Volume (30 Days)
- IMCR 265.8K
- OMCL 749.8K
- Earning Date
- IMCR 05-07-2025
- OMCL 05-06-2025
- Dividend Yield
- IMCR N/A
- OMCL N/A
- EPS Growth
- IMCR N/A
- OMCL N/A
- EPS
- IMCR N/A
- OMCL 0.45
- Revenue
- IMCR $333,581,000.00
- OMCL $1,135,755,000.00
- Revenue This Year
- IMCR $20.26
- OMCL $3.75
- Revenue Next Year
- IMCR $8.49
- OMCL $4.42
- P/E Ratio
- IMCR N/A
- OMCL $56.92
- Revenue Growth
- IMCR 25.75
- OMCL 3.00
- 52 Week Low
- IMCR $23.15
- OMCL $22.66
- 52 Week High
- IMCR $62.22
- OMCL $55.75
- Technical
- Relative Strength Index (RSI)
- IMCR 45.68
- OMCL 28.65
- Support Level
- IMCR $27.88
- OMCL $22.66
- Resistance Level
- IMCR $31.38
- OMCL $32.18
- Average True Range (ATR)
- IMCR 1.60
- OMCL 1.17
- MACD
- IMCR -0.08
- OMCL -0.46
- Stochastic Oscillator
- IMCR 22.19
- OMCL 32.77
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.